Pandemic Influenza Vaccine Manufacture Preparedness Lin Su Sinovac Biotech Co., Ltd.

Slides:



Advertisements
Similar presentations
Will the Avian Flu Become the Next Epidemic?
Advertisements

0 HHS Influenza Vaccine Projects for NVAC Meeting June 7-8, 2005 By: Dr. Robin Robinson (HHS/OPHEP)
Vaccines and Related Biological Products
Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.
HHS Pandemic Influenza Vaccine Program VRBPAC Meeting Robin Robinson, Ph.D. Director, BARDA Deputy Assistant Secretary, ASPR November 14, 2012.
Wrap-up of Day 1. Plenary One: Regional and Global Update Update of global situation and response to pandemic (H1N1) Dr Wenqing Zhang Regional.
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.
Vaccination Campaigns for HPAI in China Huang Baoxu China Animal Health and Epidemiology Centre Beijing.
So Far Primarily an Avian Disease Considering geographic spread and lethality in birds – very little human disease Fear that the virus may develop the.
Pandemic Influenza: Role and Responsibility of Local Public Health Richard M. Tooker, MD Chief Medical Officer Kalamazoo County Health and Community Services.
WHO Draft Rapid Response + Containment, May 2006.
Global Vaccines 202X : Access, Equity, Ethics Panel discussion: Pandemic Influenza Preparedness Framework for the sharing of Influenza Viruses and Access.
1 PUBLIC - PRIVATE PARTNERSHIP FOR AVIAN INFLUENZA CONTROL AND PANDEMIC PREPAREDNESS Presented by Bayu Krisnamurthi Indonesia National Committee for Avian.
Clinical Outcomes of Influenza Infection Asymptomatic Asymptomatic Symptomatic Symptomatic  Respiratory syndrome - mild to severe  Involvement of major.
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
1. 2 The Public Health Agency of Canada Pandemic Influenza Preparedness: An Overview Dr. Paul Gully Deputy Chief Public Health Officer Ottawa, 19 January.
National Vaccine Advisory Committee June 7, 2005 Pandemic Influenza Vaccine Research and Development Linda C. Lambert Chief, Respiratory Diseases Branch.
Pandemic Influenza Preparedness in Chinese Taipei Center for Disease Control Department of Health Chinese Taipei Speaker: Tsung-Hsi Wang.
National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.
0 HHS Influenza Vaccine Projects for NVAC Meeting November 29-30, 2005 By: Dr. Robin Robinson Sr. Project Officer ORDC/OPHEP/DHHS.
Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.
Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.
Preparing for Pandemic Influenza Anna Lönnroth European Commission DG Research: Health Research Priority Medicines for Europe and the World.
1 Pandemic Influenza Vaccine Development Pandemic Influenza Vaccine Development sanofi pasteur R&D, France Frederick R. Vogel, Ph.D.
Division of Epidemiology 1 Pandemic Influenza: Rapid Response Required Table-top Exercise.
Ethics Conference on Asian Flu Pandemic Ethical considerations among Response to H1N1 Pandemic in China China CDC, CFETP Huilai Ma, Guang Zeng.
PANDEMIC RISK. 3 pre-requisites for a Pandemic 1. The emergence of a new virus strain with no circulating immunity within the human population 2. The.
Influenza Vaccine Development
Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,
Pandemic Influenza; A Harbinger of Things to Come Michael T Osterholm PhD, MPH Director, Center for Infectious Disease Research and Policy Associate Director,
4th Year MPharm SRP: Introduction to Pseudotype Viruses
Review and Discussion Time line courtesy of:
HHS Pandemic Influenza Preparedness Planning Julie Louise Gerberding, MD, MPH.
Dr. Zhen XU Branch of Respiratory Disease Prevention and Control Division for Disease Control and Emergency Response Chinese Center for Disease Control.
1 OIE Response to the HPAI Threat in the SADC Region 1 st SADC Meeting on Avian Influenza Pretoria, South Africa 7-9 March 2006 Sub Regional Representation.
Papua New Guinea Update 3 rd NIC Meeting 18 – 20 Beijing, China Berry Ropa National CSR Officer Department of Health Papua New Guinea.
World Health Organization, Regional Office for The Western Pacific Regional Activities Report and Preparation for the Upcoming Influenza Seasons THE 3rd.
“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.
Pandemic Response and current activities in Lao PDR NIC Meeting, Beijing, Aug 2009 Dr Phengta Vongphrachanh Director National centre for Laboratory.
Food and Drug Administration
U.S. Pandemic Influenza Preparedness and Response: Update & Progress Report “The pandemic influenza clock is ticking. We just don’t know what time it is.”
A Potential Influenza Pandemic: Possible Macroeconomic Effects and Policy Issues Julie Somers Congressional Budget Office Prepared for the Ninth Annual.
Meeting the Challenge of Pandemic Vaccine Preparedness: FDA Perspectives Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research.
America Responds: An HHS 2009-H1N1 Retrospective to Advance All Hazards Preparedness Discussion with the National Vaccine Advisory Committee June 3, 2010.
Communicable Disease Surveillance and Response, WHO Avian Influenza Credit: WHO Viet Nam.
Options for Influenza Vaccine Composition Summary of Data Options with Pros and Cons.
Current Pandemic Situation New Zealand Mark Jacobs Mark Jacobs Director of Public Health Director of Public Health Ministry of Health Ministry of Health.
1 Licensure of Pandemic Influenza Vaccines: Demonstration of Effectiveness Vaccines and Related Biological Products Advisory Committee Meeting February.
Virion Structure and Organization
FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009.
VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.
Wrap-up Day 2. Plenary Four: Pandemic and avian influenza updates Pandemic H1N1 – Origin of pandemic H1N1 virus – Genetically and antigenically homogenous.
Influenza A (H1N1) Vaccine Vaccines and Related Biological Products Advisory Committee Meeting, 23 July 2009 Raburn Mallory, M.D. Proprietary Vaccines.
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY.
Pandemic Vaccines Current and Future Issues 30 January 2007 Beijing Keiji Fukuda Global Influenza Programme.
Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute.
1 H5N1 Influenza Virus Vaccine, A/Vietnam/1203/2004 (Clade 1) VRBPAC Presentation Kenneth P. Guito, MBA Strategic Project Office.
Pandemic Influenza: Planning and Preparedness Ben Schwartz, M.D. National Vaccine Program Office, U.S. Department of Health and Human Services NVAC Meeting,
1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.
Novartis Vaccines - Influenza A H1N1v vaccine development Theodore F Tsai MD MPH July 23, 2009 DHHS supported influenza cell culture vaccine production.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,
Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.
Overview of the Objectives, Expected Outcomes, and Meeting Agenda
Overview of Pandemic Influenza Planning Guide for SLTT
Case presentation of non-clinical and clinical development of vaccines
The Role of NICs in Influenza Surveillance
Research Update: The HPV Vaccines
Presentation transcript:

Pandemic Influenza Vaccine Manufacture Preparedness Lin Su Sinovac Biotech Co., Ltd

Vaccine R&D Supported by Government Pandemic influenza vaccine R&D program –National Key Technologic R&D Program, supported by China MOST, MOH, SFDA –Financially supported by National and local government

Collaboration with China CDC Pandemic influenza vaccine development was taken as an important part in Chinese National Pandemic Preparedness Plan –Sinovac signed a collaboration agreement with China CDC collaborate on vaccine development, in 2004 China CDC provided supports on basic R&D –Surveillance –Virus isolation –Constructing rg prototype strain using Chinese strain

Antigen sparing strategy –Antigen: whole virion –Adjuvant : Al –Lower dose The fast the better The more the better Technology –Reverse genetics Pre-registration vaccine –Clinical evaluation Safety/immunogenicity –Production process –China SFDA fast track approval procedure Strategy for Pandemic Vaccine

1st dose 2nd dose Pandemic Vaccine Clinical Results (1) Safety results –No SAE reported –Most reported local and systemic reactions were graded as mild and transient –The frequencies of local and systemic reactions after the second dose are significant lower than after the first dose

Pandemic Vaccine Clinical Results (2) % HI Seropositive ( % ) Day Immunogenicity results –Antibody responses were detected in 1.25/2.5/5/10 ug groups 14 days after 1st dose –Antibody responses showed a clear dose-related effect –Highest antibody responses after 2 doses were recorded in the 10 ug group: 78%

Manufacturing Capacity Expansion Plan Expand to 20 million doses per year Supported by national government Well established process Finished by the end of 2007

Epidemic vs. Capacity

Situation in China 22 cases, 14 death Numbers of outbreaks in poultry 16 billion population 20 million doses

Things need to do Enhance R&D Expand capacity Government supports Encourage public use of seasonal influenza vaccines produced in China

Thank You!